Cargando…

The value of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the prognosis of patients with hepatocellular carcinoma treated with camrelizumab: a retrospective cohort study

BACKGROUND: The Advanced Lung Cancer Inflammation Index (ALI) is considered a useful prognostic biomarker for clinical outcome in patients with malignancy. However, the prognostic value of ALI in patients with advanced hepatocellular carcinoma (HCC) is unclear. In this study we assessed the prognost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qian, Ma, Fei, Tsilimigras, Diamantis I., Åberg, Fredrik, Wang, Ju Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761123/ https://www.ncbi.nlm.nih.gov/pubmed/36544677 http://dx.doi.org/10.21037/atm-22-5099

Ejemplares similares

The prognostic value of the advanced lung cancer inflammation index (ALI) for patients with neuroblastoma
por: Qi, Can, et al.
Publicado: (2022)

The prognostic value of advanced lung cancer inflammation index (ALI) in elderly patients with heart failure
por: Yuan, Xiao, et al.
Publicado: (2022)

Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection
por: Zhang, Xin, et al.
Publicado: (2022)

Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020)

Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index (ALI) in Patients with Small Cell Lung Cancer_ Comparison with Original ALI
por: Kim, Eun Young, et al.
Publicado: (2016)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

The Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy
por: Cheng, Xi, et al.
Publicado: (2021)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment
por: Papaconstantinou, Dimitrios, et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Development of the Thalassaemia Adult Life Index (ThALI)
por: Kantaris, Xenya, et al.
Publicado: (2020)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients
por: Barth, Dominik Andreas, et al.
Publicado: (2020)

Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy
por: Chantharakhit, Chaichana, et al.
Publicado: (2021)

The Oxygenation Index compared with the P/F ratio in ALI/ARDS
por: Van Haperen, M, et al.
Publicado: (2012)

Effects of Splenectomy on Spontaneously Chronic Pancreatitis in aly/aly Mice
por: Wang, Heng-Xiao, et al.
Publicado: (2010)

A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma
por: Shi, Xiaonan, et al.
Publicado: (2023)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma
por: Serifis, Nikolaos, et al.
Publicado: (2021)

The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab
por: Liu, Jiang, et al.
Publicado: (2022)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Alí Chumacero : retrato crítico /
Publicado: (1995)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

AliPDU Upgrade
por: Mhlanga, Sibaliso
Publicado: (2014)

Alí, el maldito /
por: Aramoni, Aniceto
Publicado: (2008)

Alí, el maldito
por: Aramoni, Aniceto
Publicado: (1977)

The Immunology of Hepatocellular Carcinoma
por: Lawal, Gbemisola, et al.
Publicado: (2021)

Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab
por: Liu, Jiang, et al.
Publicado: (2023)

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020)

A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma
por: Ravindran, Nishal, et al.
Publicado: (2020)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
por: Jafri, Syed H, et al.
Publicado: (2013)

Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
por: Li, Qian, et al.
Publicado: (2023)

AliEnFS - a Linux File System for the AliEn Grid Services
por: Peters, Andreas-J., et al.
Publicado: (2003)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients
por: Xu, Litao, et al.
Publicado: (2017)

AliPDU Package Upgrade
por: "Martin, Michael
Publicado: (2015)

AliPDU Package Upgrade
por: Martin, Michael
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_obfbk5kji2nb7prqes5iru1udt